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INTRODUCTION
Despite advances in the treatment of primary 
tumours, the incidence of secondary tumours (metastases) 
is increasing, particularly in the brain [1]. Brain metastases 
occur in over 20% of cancer patients, with the most 
common primary cancers to spread to the brain being lung, 
breast and melanoma. 
A significant hurdle, however, to the development 
of effective brain metastasis therapies is the lack of 
in vitro and in vivo studies that accurately recapitulate 
the multistep pathogenesis. We have previously reported 
the development of in vivo models of breast cancer brain 
metastasis that enable investigation of the mechanisms 
involved in both the initial stages of seeding to the brain 
and downstream proliferation stages within the brain 
parenchyma [2, 3]. In those studies we have shown marked 
and early upregulation of specific subsets of cell adhesion 
molecules (CAMs) [3]. However, the contribution of 
CAM-mediated pathways to tumour growth within the 
brain parenchyma, following extravasation from the 
bloodstream, remains unclear. One molecule, in particular, 
that showed marked and consistent upregulation in our 
experimental models was intercellular cell adhesion 
molecule-1 (ICAM-1) [3]. This cell surface glycoprotein 
is typically expressed by both endothelial and immune 
system cells and its role in inflammatory processes has 
been widely described [4]. At the same time, leukocyte 
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ABSTRACT
Over 20% of cancer patients will suffer metastatic spread to the brain, and 
prognosis remains poor. Communication between tumour cells and host tissue is 
essential during metastasis, yet little is known of the processes underlying such 
interactions in the brain. 
Here we test the hypothesis that cross-talk between tumour cells and host 
brain cells, through tumour cell leukocyte function associated protein-1 (LFA-1), 
is critical in metastasis development. Temporal expression of LFA-1 and its major 
ligand intercellular adhesion molecule-1 (ICAM-1) was determined in two different 
mouse models of brain metastasis. Marked upregulation of both proteins was found,  
co-localising with astrocytes, microglia and tumour cells themselves. Silencing of LFA-1  
expression in MDA231Br-GFP cells prior to intracerebral injection resulted in > 70% 
reduction in tumour burden compared to control MDA231Br-GFP cells (p < 0.005, n = 5).  
Subsequent qRT-PCR analysis of brain tissue revealed significant reductions in COX-2,  
VEGF and eNOS from host brain tissue, but not tumour cells, in mice injected with 
LFA-1 knockdown cells (p < 0.0001, n = 5). Finally, expression of both LFA-1 and 
ICAM-1 was demonstrated in human brain metastasis samples. 
The results of this study suggest LFA-1 as a new target in brain metastasis 
therapy and highlight the potential synergy with current anti-COX-2 and anti-NOS 
therapies.
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function associated protein 1 (LFA-1, also known as CD11a-
CD18 and αLβ2), a cognate ligand to ICAM-1 [5], was also 
strongly upregulated, particularly on tumour cells [3]. 
Involvement of LFA-1/ICAM-1 in the immune 
response against cancer cells has been indicated both 
in vitro [6] and, more recently, in vivo [7, 8]. In particular, 
LFA-1 has been extensively described as having an 
essential role in leukocyte extravasation at cancer sites 
[9], whilst other studies have suggested a requirement 
for LFA-1/ICAM-1 interactions between melanoma and 
endothelial cells to aid transmigration of tumour cells [10]. 
However, no studies to date have specifically considered 
the role of LFA-1-mediated pathways during metastasis 
growth within the brain, once extravasation across the 
blood-brain barrier (BBB) has occurred, and it remains 
unclear whether these are pro- or anti-tumorigenic.
In recent years, immunotherapy has gained credence 
as a strategy for cancer treatment, with multivariate 
approaches using adjuvant radio- and chemotherapy 
[11, 12]. Although not currently undergoing trials in 
cancer therapy, LFA-1 has been the object of intense study 
in a number of clinical trials [12], with different modes 
of application including antibody therapy (Odulimomab), 
small molecules (SAR1118) and siRNA approaches [13]. 
Taken together, these studies suggest that this particular 
integrin may be an attractive target in the clinic and may 
have, hitherto unexplored, potential in brain metastasis.
Based on the above findings, we hypothesised that 
signalling between LFA-1 on tumour cells and ICAM-1, 
or its alternative ligands ICAM-2, ICAM-3, ICAM-4 
and junctional adhesion molecule-1 (JAM-1) [14, 15], 
contribute to successful tumour growth within the brain 
parenchyma, and that molecules within the LFA-1 
signalling pathways may provide potential therapeutic 
targets in brain metastasis. 
RESULTS
Expression of LFA-1 and ICAM-1 in mouse 
brain metastasis models
In the syngeneic 4T1-GFP model, increased 
expression of both LFA-1 and ICAM-1 was observed 
throughout the time-course and exhibited similar stable 
patterns of expression (Figure 1A and 1B). Both CAMs 
co-localised with astrocytes and microglia, whilst only 
ICAM-1 co-localised with endothelial cells. (Figure 1C 
and Table 1). Similar expression of LFA-1 and ICAM-1 
was observed in the MDA231BR-GFP model at 14 
days after tumour induction to that seen at 10 days after 
tumour induction in the 4T1-GFP model (Figure 1D–1I); 
expression of both CAMs was evident not only within 
the tumour area, but also spreading beyond the tumour 
margins throughout the striatum (Figure 1D–1E). No 
detectable expression of either ICAM-1 or LFA-1 was 
seen in the contralateral hemisphere (Figure 1D–1E) or in 
vehicle-injected mice (Supplementary Figure S1). 
LFA-1/ICAM-1 expression in human brain 
metastasis samples
To determine the clinical relevance of the 
above findings, brain metastasis samples from breast 
carcinoma patients were assessed for hLFA-1 and 
hICAM-1 immunostaining. Additionally, brain metastasis 
samples from lung adenocarcinoma patients were also 
immunostained to determine the broader applicability of 
LFA-1 as a target in brain metastasis. In breast cancer 
patients, marked LFA-1 expression was evident within 
and around brain metastasis foci (Figure 2A–2B) whilst 
ICAM-1 was found predominantly around the micro-
metastasis with a more widespread pattern (Figure 2C); 
as for the mouse models, expression of LFA-1 appeared to 
primarily co-localise with tumour cells (Figure 2D–2E), 
and ICAM-1 seemed to be expressed in more brain 
cell types (Figure 2F). At the same time, in lung 
adenocarcinoma samples, LFA-1 expression was also 
clearly upregulated in metastatic regions (Figure 2G–2H 
and 2J–2K), whereas ICAM-1 was detected primarily 
at the intersection between tumour cells and brain 
parenchyma (Figure 2I and 2L).  All samples showed 
positive staining for both LFA-1 and ICAM-1.
Effect of LFA-1 knockdown in vitro and in vivo
To determine the role of LFA-1 on tumour cells 
during metastatic growth in the brain, LFA-1 expression 
was knocked down in the MDA231Br-GFP cells by 
shRNA transfection. Given the concordance of CAM 
expression in the two experimental models, the human cell 
line was used for subsequent studies to enhance clinical 
relevance. Quantitatively, similar LFA-1 expression 
levels were evident in vitro in the parent MDA231Br-GFP 
(MDA) cells and those transfected with control shRNA 
plasmids (shS and shE), whilst cells transfected with the 
two anti-LFA-1 shRNA plasmids showed a significant 
drop in LFA-1 expression (~50%, p < 0.05–0.01, 
KD#1 and KD#2; Figure 3A–3B). No changes in either 
in vitro growth rates or cell activity were detected in 
any experimental cell line with respect to the parental 
MDA231Br-GFP cells (Supplementary Figure S2).
In the in vivo studies, mice injected with MDA, 
shS or shE cells exhibited similar tumour growth patterns 
(Figure 3C and 3D), whilst the animals injected with 
the LFA-1 knockdown cells (KD#1 and KD#2) showed 
significantly reduced tumour growth (Figure 3C–3F). 
Decreased growth was evident both in terms of tumour 
area (~70%, p < 0.05; Figure 3C) and rostro-caudal 
growth (< 50%, p < 0.05–0.01; Figure 3D). In order to 
elucidate whether the LFA-1 knockdown resulted in 
prolonged tumour growth inhibition, rather than just 
an initial suppression, a later time point (day 21 post-
tumour cell injection) was assessed. Notably, a similar 
pattern of reduced tumour area was evident in the animals 
injected with LFA-1 knockdown cells (KD#1 and KD#2) 
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Figure 1: Time-course study of the percentage of expression of  LFA-1 (A) and ICAM-1 (B) within the tumour area, 
in BALB/c and SCID mice injected intracerebrally with 5 × 103 4T1-GFP or MDA231Br-GFP cells, respectively. Data 
were acquired at days 5, 10, 21 and 35 for the 4T1-GFP model, and at day 14 for the MDA231Br-GFP model (n = 6 per time point). Results 
are expressed as the percentage area of LFA-1 expression (A) and ICAM-1 (B) as a function of the total tumour area for each time-point. 
A minimum of 8 sections per animal (n = 6), evenly distributed through the striatum, were used to quantify the presence of each CAM. 
Statistical significances across the 4T1-GFP time-course study were determined by one-way ANOVA, with Tukey post-hoc tests.  (C) 
Triple-colour fluorescence images showing co-localisation between LFA-1 and ICAM-1 (red) in the syngeneic (4T1-GFP) mouse model 
and different cellular markers (blue): CD34 for endothelial cells, GFAP for astrocytes and Iba-1 for microglia. Tumour cells were GFP 
positive (green). Magenta (white arrows) indicates co-localisation between CAMs and cellular markers (arrows). Scale bars = 50 µm. 
(D–E) Representative photomicrographs showing immunohistochemical detection of LFA-1 (D) and ICAM-1 (E) at day 10 in BALB/c 
mice injected with 4T1-GFP cells (upper row) and at day 14 in SCID mice injected with MDA231BR-GFP cells (lower row); injected (left) 
and control (right) hemispheres shown. Scale bars = 200 µm. (F–G) Representative photomicrographs showing in higher resolution the 
expression of LFA-1 in BALB/c injected with 4T1-GFP cells (F) and SCID mice injected with MDA231BR-GFP cells (G). Scale bars = 
100 µm. (H–I)  Representative photomicrographs showing in higher resolution the expression of ICAM-1 in BALB/c injected with 4T1-
GFP cells (H) and SCID mice injected with MDA231BR-GFP cells (I). Scale bars = 100 µm.  
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in comparison to parental MDA231Br-GFP (MDA) and 
control knockdown animals (shE and shS; Supplementary 
Figure S3).
Effect of LFA-1 knockdown on LFA-1 signalling 
pathways in vivo 
The intercommunication between LFA-1 on tumour 
cells and ICAM-1 (or alternative ligands, ICAM-2/ICAM-
3/ICAM-4/JAM-1) on other cells in the local vicinity 
triggers signalling through several pathways on each side 
[16]. Therefore, we investigated the expression of a panel 
of different genes that have previously been implicated 
either in LFA-1/ICAM-1 signalling in other tumour types or 
in metastatic spread of breast cancer [17–20]. These genes 
were assessed for both host tissue (mouse) and tumour 
cell (human) origin. Quantitation of mRNA levels in the 
injected striatum of each experimental group indicated that 
mouse COX-2, VEGF and endothelial NOS (eNOS) were 
all significantly reduced in animals injected with KD#1 or 
KD#2 compared to both the MDA and shS groups (Figure 
4A–4C), and were not significantly different to the PBS 
injected controls. Interestingly, inducible NOS (iNOS) 
levels were similar for all groups injected with MDA231Br-
GFP cells (MDA, shS, KD#1 and KD#2), irrespective of 
LFA-1 knock down, and in all cases were significantly 
elevated from control levels (Figure 4D). Mouse TGF-β 
showed no changes in any groups injected with tumour 
cells compared to PBS-injected controls (data not shown).
In contrast to the changes in mouse genes observed, 
no changes were evident in any of the human genes studied 
between mice injected with parental MDA231BR-GFP 
cells and knock-down clones; TGF-β, VEGF, eNOS, iNOS 
and COX-2 (Supplementary Figure S4A–S4E). Whilst 
we cannot exclude the possibility of changes below the 
sensitivity threshold of the experiment, we are confident 
that no substantial changes in human gene expression 
occurred since we were able to detect changes in human 
vimentin (Supplementary Figure S4F) in the MDA and 
shS groups, compared to the PBS injected controls. 
Assessment of human CXCL12 and mouse CXCR4 
mRNA further confirmed that the hCXCL12/mCXCR4 
axis was not altered by disruption of LFA-1 interactions 
with the brain environment; no changes evident in any of 
the groups (Supplementary Figure S4G–S4H).
Cellular localisation of COX-2 
To confirm the reduction in expression of COX-2 
within the tumour environment following LFA-1 
knockdown in tumour cells, and to determine its cellular 
origin, serial co-localisation of COX-2 with astroglia, 
microglia, endothelial cells and neurons was assessed. 
In mice injected with the parent MDA231Br-GFP cells, 
COX-2 predominantly co-localised with astrocytes 
(Figure 5A, 5I), with lower levels of co-localisation 
evident on neurons (Figure 5B, 5I), endothelial cells 
(Figure 5C, 5I) and microglia (Figure 5D, 5I). In animals 
injected with LFA-1 knockdown tumour cells, the levels 
of COX-2 were significantly reduced in astrocytes (~80% 
reduction; Figure 5E, 5I), neurons (~65% reduction; 
Figure 5F, 5I) and endothelial cells (~60% reduction; 
Figure 5G, 5I) compared to animals injected with the 
parent MDA231Br-GFP cells. In contrast, levels of COX-2 
in microglia remained unchanged in all tumour-cell 
injected animals (Figure 5H, 5I). For the most part, COX-2 
expression was evident in cells in direct contact with tumour 
cells. In some cases, expression appeared to extend to cells 
in close proximity to the tumour margin, but this may be an 
artefact arising from analysis of single sections in which the 
location of tumour cells in adjacent sections is unknown.
In vivo assessment of NO release and p53 
quantitation
Changes in NO release during tumour growth 
were further assessed via NT analysis in four groups of 
animals: MDA, shS, KD#1 and KD#2 (Figure 6A–6B). 
MDA and shS groups showed similar levels of NT within 
the tumour area, whilst animals injected with KD#1 and 
KD#2 showed a significant reduction in NT expression 
(> 75%; Figure 6C).
Given the reported links between NO and p53 
[21–23], the effect of reduced NO production on p53 
expression following LFA-1 knockdown was also 
assessed (Figure 6D–6F). In contrast to NT levels, p53-
DINP expression within the tumour area was significantly 
Table 1: Summary of biomarker expression and co-localisation with endothelial cells, astrocytes, 
microglia and tumour cells in the syngeneic 4T1-GFP model
% Expression Endothelium Astrocytes Microgila TC
LFA-1 33.2 ± 10.4 – + + +
ICAM-1 44.5 ± 7.7 + + + +
The first column shows the area of expression (mean ± SEM) for each adhesion molecule within the tumour area, observed 
at day 21 post-injection. A minimum of 8 sections per animal (n = 6 per time-point), evenly distributed through the striatum, 
were used to quantify the presence of each CAM within the tumour area; expression was quantified as the percentage of 
tumour area covered using an unbiased algorithm in imagescope, which detects positive brown pixels. The remaining 
columns indicate co-localisation of each adhesion molecule with endothelium (CD34), astrocytes (GFAP), microglia (Iba-1) 
and tumour cells (TC; GFP).
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Figure 2: Photomicrographs of human breast carcinoma. (A–F) and lung adenocarcinoma (G–L) brain metastasis resections 
stained immunohistochemically against LFA-1 (A–B and G–H) and ICAM-1 (C and I); higher magnification images from boxes shown 
in D–F and J–L. Scale bars = 50 µm. Widespread expression of LFA-1 is evident on tumour cells (brown staining; arrows, D and J) whilst 
ICAM-1 is evident on the intersection between tumour cells and brain parenchyma (brown staining; arrows, F and L). Immunofluorescence 
images of human breast cancer brain metastasis (B, E) and lung adenocarcinoma brain metastasis (H, K) demonstrate co-localisation 
(arrows) of LFA-1 (red) with tumour cells (blue; DAPI nuclear stain). Surrounding astrocytes stained green. Scale bar = 50 µm. 
increased in mice injected with LFA-1 knockdown tumour 
cells (55-65% tumour area) compared to the MDA and 
shS groups (~30% tumour area; Figure 6F).  In order to 
assess potential changes in p53 expression over time, a 
second group of animals was assessed at a later time point 
(day 21, n = 3 per group). Again, significantly greater p53 
staining was evident in KD#1 and KD#2 groups (≥70% 
tumour area) than the MDA and shS groups (~40% tumour 
area; Supplementary Figure S5).
In vitro assessment of NO and p53 expression
A significant increase in NO production by both 
mouse and human endothelial cells was evident following 
incubation with VEGF compared to control untreated cells 
(Figure 7A). Co-culture of MDA231Br-GFP cells with 
VEGF-treated human or mouse endothelial cells showed 
reduced levels of p53-DINP in the tumour cells compared 
to incubation with untreated endothelial cells (Figure 7B). 
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Figure 3: (A) Western blot showing the levels of LFA-1 protein expression in the five different experimental groups.  Parental 
MDA231Br-GFP (MDA), scrambled shRNA (shS), empty shRNA (shE) and two different clones with significant reduction of LFA-1 
expression, KD#1 and KD#2. (B) Quantitation of the mean intensity of each band with respect to the parental MDA231Br-GFP. Band 
densitometry was normalised to the intensity of tubulin bands and quantified across three independent experiments. Statistical significance 
was determined by one-way ANOVA, with Tukey post-hoc tests. *p < 0.05 and **p < 0.01.  (C) Quantitation of tumour growth in animals 
injected intrastriatally with parental MDA231Br-GFP cells (MDA), control knockdown cells (empty cassette, shE; and scramble cassette, 
shS) or LFA-1 knockdown cells (KD#1 and KD#2) (n = 5 per group). Growth is expressed as tumour area/μm2 brain area analysed. 
Statistical significance determined by one-way ANOVA, with Tukey post-hoc tests. *p < 0.05 and **p < 0.01. (D) Quantitation of rostro-
caudal tumour growth through the striatum in the same animals as for (C). Statistical significance determined by one-way ANOVA, with 
Tukey post-hoc tests. *p < 0.05, **p < 0.01. (E–F) Representative photomicrographs of brain sections from animals injected intracerebrally 
with parental MDA231Br-GFP (MDA, E) or KD#1 (F) cells; sections stained with cresyl violet and tumour foci are circumscribed in green. 
Inset shows higher magnification of the tumour colonies in boxed regions.
DISCUSSION
Communication between tumour cells and the host 
tissue is essential to overcome the challenges of growing 
within the specialised environment of the brain. This 
work has demonstrated that inhibition of tumour-brain 
cell communication through downregulation of LFA-1 in 
tumour cells causes a significant reduction in metastasis 
growth. This inhibition of tumour growth was associated 
with reduced endothelial NO and increased tumour 
p53 production, which may result directly or indirectly 
from the reduction in COX-2 and VEGF expression 
observed in LFA-1 knockdown groups. Notably, resected 
human samples from both breast and lung cancer brain 
metastasis, the two most common primary ‘brain-seeking’ 
cancers [24], indicated the presence of LFA-1 and ICAM-
1 on tumour cells and brain parenchyma, respectively, 
supporting the potential translation of these findings into 
brain metastasis therapies. 
In this study, our aim was to specifically investigate 
processes involved in the post-extravasation stages of 
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metastasis development in the brain and the role of 
tumour-host cell communication during this phase. To 
achieve this, we utilised a previously validated model of 
direct tumour cell injection into the brain parenchyma 
[25]. We achieved a single focal area of metastatic growth, 
which exhibited similar growth patterns to those observed 
following haematogenous dissemination to the brain 
(Supplementary Figure S6), and corresponding patterns 
of CAM expression [3]. 
Cell adhesion molecules have been shown to be 
essential in the bi-directional communication between 
metastatic cells and brain tissue [26–28]. However, the 
majority of previous studies on LFA-1 have focussed on 
its involvement in the immune system response to disease 
and injury. Our results indicate a novel role for LFA-1 
as a key mediator between tumour and host cells during 
metastatic growth in the brain. Both ICAM-1 and LFA-1 
have been shown to be involved in transendothelial tumour 
growth in melanoma in vitro models [10]. However, little 
is known of their role in the downstream proliferative 
steps of brain colonisation by metastatic tumour cells. In 
this study, LFA-1 expression was found in tumour cells, 
microglia and astrocytes, but not endothelial cells. In 
turn, as shown previously [3], ICAM-1 expression was 
evident on all cell populations. Given previous work 
indicating involvement of tumour cell LFA-1 expression in 
lymphoma [29] and liver metastasis [7], we hypothesised 
that owing to the presence of LFA-1 on breast cancer 
cells, knocking down LFA-1 expression in the tumour 
cells would impair interactions with host tissue cells, 
primarily through ICAM-1 interaction, and alter tumour 
colonisation in the brain. In accord with this hypothesis, 
animals injected intracerebrally with LFA-1 knockdown 
MDA231Br-GFP cells showed a significant reduction in 
tumour growth in comparison with the parent MDA231Br-
GFP cells. These findings indicate a central role for LFA-1 
signalling in brain metastasis and suggest new potential 
therapeutic targets.
To understand the downstream consequences of 
inhibiting binding between LFA-1 on tumour cells and its 
ligands, both on host brain cells and other tumour cells, we 
assessed expression of seven predominant genes in LFA-
1-induced signalling pathways. Interestingly, no change 
in any of the human genes (tumour cell origin) studied 
was found, whilst expression of several mouse genes (host 
tissue origin) was evident. These findings suggest that 
LFA-1 knockdown in tumour cells had a greater effect on 
tumour-brain cell communication, than on tumour-tumour 
Figure 4: Quantitative reverse transcription PCR analysis of mouse gene expression in the striatum of mice injected 
with either PBS or one of the MDA231Br-GFP clones (n = 5 per group). Statistical significance determined by one-way 
ANOVA, with Tukey post-hoc tests. Multiple Comparison Test: a = significant compared to the PBS group; b = significant compared to the 
control MDA231Br-GFP group; and c = significant compared to the shS group. *p < 0.05 – 0.001. 
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cell communication, although we cannot exclude the 
possibility that other genes in these pathways (including 
those in tumour cells) are involved. One important 
pathway that has been shown to be involved in breast 
cancer dissemination to distant organs is the CXCL12/
CXCR4 axis [18, 20]; however, in our brain metastasis 
models neither of these genes showed significant changes. 
A number of reports have also suggested a role for both 
LFA-1 and ICAM-1 in VEGF production [17, 30, 31]. 
In vitro studies have shown that LFA-1 expression on 
tumour cells facilitates interactions between tumour 
cells and the environment, and contributes to increased 
release of VEGF through a COX-2 dependent mechanism 
[17, 32, 33]. In accord with those findings, the current 
study has demonstrated a marked reduction in COX-2 
expression, primarily in astrocytes, together with reduced 
Figure 5: Immunofluorescent images of brain sections from animals injected with either MDA231Br-GFP (MDA) or 
LFA-1 knockdown (KD#1) cells showing COX-2 (green) co-localisation (arrows) with different brain cell populations 
in red: (A, E) astrocytes, GFAP; (B, F) neurons, NeuN; (C, G) vessels, CD34; and (D, H) macrophages/microglia, 
F4/80. Cell nuclei are stained with DAPI (blue). Scale bars = 100 µm  (I) Quantitative analysis of COX-2 co-localisation with different 
brain cell populations in animals injected with either MDA231Br-GFP (MDA; white bars) or LFA-1 knockdown (KD#1; black bars) cells 
(n = 4). Statistical significance determined by one-way ANOVA, with Tukey post-hoc tests. **p < 0.01, ***p < 0.005. 
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VEGF gene expression in animals in which LFA-1 
signalling was disrupted. At the same time, reduced VEGF 
production was associated with downregulation of eNOS 
and NO release, supporting the concept of VEGF-driven 
eNOS activity, as previously reported [33]. In comparison, 
inducible NOS (iNOS) was significantly elevated in all 
groups compared to vehicle injected controls, and no 
difference was observed following LFA-1 knockdown. 
These data are in line with an inflammatory driver for 
iNOS production that is independent of the LFA-1/ICAM-
1(ICAM-2/ICAM-3/ICAM-4/JAM-1) axes. Moreover, 
the reduction in NO production within the metastasis 
microenvironment suggests that the reduction in eNOS 
activity outweighed any increase in iNOS activity.
Figure 6: (A–B) Photomicrographs of brain sections showing NT staining within the striatum from a representative animal 
in each group: MDA (A) and KD#1 (B). Scale bars = 100 µm. (C) Quantitative analysis of the area of nitrotyrosine (NT) staining per 
mm2 tumour area in animals injected with MDA231BR-GFP cells (MDA), control knockdown cells (sh S), or LFA-1 knockdown cells 
(KD#1 and KD#2) at day 14 after intracerebral injection (n = 4). Statistical significance determined by one-way ANOVA, with Tukey post-
hoc tests; *p < 0.05. (D–E) Photomicrographs of brain sections showing p53 staining within the striatum from a representative animal in 
each group: MDA (D) and KD#1 (E). Scale bars = 100 µm.  (F) Quantitative analysis of p53 expression within the tumour area in animals 
injected with MDA231Br-GFP cells (MDA), control knockdown cells (shS), or LFA-1 knockdown cells (KD#1 and KD#2) at day 14 after 
intracerebral injection (n = 4). Statistical significance determined by one-way ANOVA, with Tukey post-hoc tests: *p < 0.05 and **p < 0.01. 
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NO can have both anti- or pro-tumourigenic properties 
in cancer biology, depending on the type of tumour, its 
genetic background, the duration and level of exposure to 
NO, the site of production (tumour cells vs. host tissue) 
and which enzyme isoform prevails [21]. In some primary 
tumours, such as colon adenocarcinoma or lymphoma, 
tumour-derived NO promotes tumour progression [34, 35], 
primarily through an up-regulation of iNOS leading to a 
more proliferative and invasive tumour phenotype due to 
impairment of p53-induced apoptosis [35, 36]. In contrast, 
host-derived NO in ovarian cancer has been shown to 
inhibit tumour growth, depending on the levels of NO [37], 
and it has also been shown to exhibit protective effects on 
mesencephalic cells [38]. Here, our findings suggest that, in 
the context of brain metastasis, the high level of NO detected 
around the metastatic colonies in animals injected with 
parental MDA231Br-GFP cells is pro-tumorigenic. 
It has been shown that low dose exposure to NO in 
certain types of cancer activates p53 and leads to tumour 
cell apoptosis; this effect likely results from induction of 
DNA damage by NO and its derivatives [39]. In accord 
with this, we found a marked increase in p53-DINP1 
expression in mice injected with LFA-1 knockdown 
MDA231Br-GFP cells, together with significantly reduced 
tumour growth. MDA-MB-231 cells, are the progenitors 
of MDA231Br cells, and possess high levels of mutant 
p53 (mp53) which can contribute to the suppression of 
apoptosis in deprived conditions [40]. However, mp53 
can also elicit cell cycle arrest and apoptosis in more 
efficient ways than wild-type p53 (wtp53) in other tumour 
cell types [41, 42]. In the current study, reduced levels 
of NO in animals injected with LFA-1 knockdown cells 
were associated with reduced metastasis growth and an 
increase in p53-DINP1. We were unable to differentiate 
Figure 7: (A) Fluorescence quantitation of NO presence in human (hCMEC) and mouse (sEND1) endothelial cell lines 
+/– 48 h incubation with VEGF. *p < 0.05. (B) Western-blot showing p53 levels in MDA231Br-GFP cells after 72 h co-culture with 
hCMEC or sEND1 endothelial cells, respectively, +/– pre-activation of endothelial cells with VEGF. (C) Quantitation of p53 DINP1 levels 
in MDA231Br-GFP cells. Experiments were run in triplicate and statistical significance determined by t student: *p < 0.05. (D) Schematic 
illustrating putative activation of LFA-1 signalling pathways during metastatic growth in the brain. (1) The integrin LFA-1 on tumour cells 
interacts with its cognate ligand ICAM-1 (or alternative ligands ICAM-2, ICAM-3, ICAM-4 and JAM-1) on astrocytes, microglia, neurons 
and endothelial cells. (2) This interaction supports tumour growth by up-regulating COX-2 expression (predominantly in astrocytes) and 
consequent release of VEGF. (3) VEGF is taken up by endothelial cells and upregulates expression of endothelial NOS (eNOS). (4) The 
resultant increase in nitric oxide release impairs p53, potentially leading to enhanced tumour growth.
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between mp53 and wtp53, but the measured increase 
in p53 expression coupled with reduced tumour growth 
may suggest an mp53-driven and/or wtp53-driven pro-
apoptotic gain-of-function. We also cannot exclude 
the possibility that increased nuclear p53 expression in 
tumour cells forced a negative feedback-loop on eNOS 
expression, thus reducing NO-induced DNA damage [39]. 
Taken together, our findings suggest the potential 
for targeting the LFA-1/COX-2/NOS axis therapeutically 
in brain metastasis. Anti-LFA-1 therapies have been 
taken into clinical trials for a number of conditions, 
including psoriasis [43], transplant rejection [44] and 
dry-eye syndrome [45]. However, no studies to date have 
pursued LFA-1 as a therapeutic target in either primary or 
secondary brain cancer. In contrast, a number of studies 
have demonstrated that tumour growth can be altered 
by inhibition of NOS, both in vitro and in vivo, although 
most of these studies sought to modulate iNOS rather than 
eNOS activity [46, 47]. Nevertheless, NO inhibitors have 
been shown to reduce tumour angiogenesis and blood 
flow in tumour-bearing mice [48]. Other studies have 
shown that the combination of COX-2 and NOS inhibitors 
reduces tumour growth in colon cancer [49], whilst 
patients on daily aspirin (non-selective COX inhibitor) 
suggest a reduced long-term risk for both primary and 
secondary cancers [50, 51]. Similarly, specific COX-2 
inhibitors have been shown to induce apoptosis in lung 
carcinoma cells and reduce invasiveness in liver metastasis 
[52, 53]. Our data strongly support the concept that such 
strategies blocking NOS (e.g. L-NAME) and/or COX-2 
(e.g. NS-398) may be highly beneficial in the treatment of 
brain metastasis. 
In summary, we have demonstrated that disruption of 
tumour-host interactions via LFA-1 knockdown in tumour 
cells, dramatically reduces breast cancer metastasis within 
the brain. Moreover, this significant reduction in growth is 
associated with a decrease in COX-2 expression, primarily 
in astrocytes, and a downstream reduction in endothelial 
NO production. These findings suggest a potential 
scenario whereby under normal conditions, cross-talk 
between tumour cells and the brain parenchyma, by LFA-
1 activated pathways, leads to increased COX-2 activity, 
VEGF expression and endothelial NO release, with a 
downstream reduction in tumour p53 levels (illustrated in 
Figure 7C), which warrants further investigation. LFA-1 
was upregulated in human brain metastasis tissue from 
both breast and lung cancer patients supporting the clinical 
relevance of our findings. Together, these data provide 
strong evidence for pathways triggered by LFA-1 as a 
potential target for treating brain metastasis, and suggests 
the potential not only for anti-LFA-1 treatments, but also 
pre-existing anti-COX-2 or anti-NOS therapies.
MATERIALS AND METHODS
In vivo models of brain metastasis
All experiments were approved by the UK Home 
Office. Female BALB/c mice were anaesthetised 
with 2–3% isoflurane in 70% N2:30% O2, placed in a 
stereotactic frame and focally microinjected in the left 
striatum (+0.5 mm and 1.5 mm lateral from Bregma; 
depth 2.5 mm) with 5 × 103 4T1-GFP cells, a syngeneic 
metastatic mouse mammary carcinoma cell line, in 0.5 µl 
PBS using a 75 µm-tipped glass microcapillary (Clark 
Electromedical Instruments, UK). Animals were perfused 
at day 5, 10, 21 or 35 after tumour cell injection (n = 6 
per time-point per group). To assess conservation of 
CAM expression across different tumour cell lines, and 
potentially extrapolate the data into the clinic, 5 × 103 
MDA231Br-GFP tumour cells, a metastatic human breast 
carcinoma cell line (kind gift from Dr P. Steeg, USA), 
were injected into female SCID mice as above (n = 5); 
animals were perfused at a single time-point, 14 days post-
injection. Control BALB/c and SCID mice were injected 
with 0.5 µl saline, into the left striatum, as above (n = 3).
Immunohistochemical and immunofluorescent 
analysis of mouse tissue
At the end of each experiment animals were 
transcardially perfusion-fixed under terminal anaesthesia 
with 0.9% heparinised saline followed by 200 ml of 
periodate lysine paraformaldehyde (PLP) containing only 
0.025% glutaraldehyde (PLPlight). Brains were post-fixed, 
cryoprotected, embedded and frozen in isopentane at 
–40°C. Expression of ICAM-1 and LFA-1 was assessed 
immunohistochemically on eight sections per animal 
(n = 6 per time point and group). Briefly, sections were 
washed in phosphate-buffered saline (PBS; Thermo Fisher 
Scientific, UK; pH 7.4) and quenched using 1% hydrogen 
peroxide (Sigma Aldrich, UK) in methanol. Sections were 
blocked and then incubated for 16 h with the appropriate 
primary antibody: anti-LFA-1 (1:250, Abcam-186873-, 
UK) and anti-ICAM-1 antibody (1:400, Abcam-124759-, 
UK). After rinsing in PBS, slides were incubated for 1h 
with the appropriate secondary antibody: biotinylated 
polyclonal to rabbit raised in goat (1:200, Vector Labs, 
CA, USA). After washing with PBS, staining was detected 
using a standard DAB/hydrogen reaction and sections 
were counterstained with cresyl violet. Slides were 
mounted and coverslipped using DPX mounting solution 
(Thermo Fisher Scientific, UK). A minimum of 8 sections 
per animal (n = 6 per time-point), evenly distributed 
through the striatum, were used to quantify the presence 
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of each CAM; expression was quantified as the percentage 
of tumour area covered using an unbiased algorithm in 
Imagescope, which detects positive brown pixels.
To identify cell populations involved in the 
metastatic process, immunofluorescent co-localisation 
of LFA-1 and ICAM-1 with endothelial, glial or tumour 
cells was assessed using secondary antibodies labelled 
with different fluorophores (AMCA or Cy3). Sections 
were incubated for 16 h at 4°C with primary antibodies to 
LFA-1 or ICAM-1 (as above), and to one of the following 
cell markers: anti-CD34 (1:200, Abcam, UK); anti-GFAP 
(1:300, Dako, Denmark); anti-Iba1 (1:200, Abcam, UK). 
Slides were rinsed with PBS and incubated for 30 min 
with the appropriate secondary antibody in TNB (Tris-
NaCl-Blocking buffer): biotinylated polyclonal antibody 
to rabbit (1:200, Vector Labs, CA, USA), biotinylated 
polyclonal to rat (1:200, Vector Labs, CA, USA) or 
biotinylated polyclonal antibody to goat (1:200, Vector 
Labs, CA, USA). Sections were then washed with 
PBS, incubated with streptavidin-HRP (PerkinElmer; 
1:200) in TNB for 30 min, washed and incubated 
for 8 min in the dark with TSA-biotin (PerkinElmer; 
1:100) in amplification buffer (PerkinElmer). Slides 
were washed and incubated with a streptavidin-A488 
fluorophore (Invitrogen; 1:100) for 30 min. To detect 
the other fluorophore, the Texas Red secondary antibody 
(Vector Laboratories) was added at the same time as 
streptavidin-A488. Slides were counterstained using DAPI 
1:1000 (Vector Laboratories) and cover-slipped using 
Vectashield mounting medium (Vector Laboratories). 
To detect the cellular source of COX-2, 
immunofluorescent co-localisation of COX-2 with 
different brain cell populations was assessed within and 
around metastasis areas, for the MDA (n = 4) and KD#1 
(n = 4) groups. Co-localisation of COX-2 presence with 
astrocytes (GFAP, 1:300, DAKO, UK), neurons (NeuN, 
1:500, Millipore, USA), vessels (CD34, 1:200, Abcam, 
UK) and macrophages/microglia (F4/80, 1:100, Abcam, 
UK) was quantified using 5 intra- and peri-tumoural ROI 
per animal. The anti-COX-2 antibody (1:100, Abcam, 
UK) was tagged with Alexa488 (1:200, Vector, UK), and 
a Texas Red fluorophore (1:100, Vector, UK) was used for 
the rest of the antibodies. 
All immunofluorescent images were acquired 
using an inverted confocal microscope (LSM-710; Carl 
Zeiss Microimaging) and analysed using ImageJ (NIH). 
Detection ranges were set to eliminate crosstalk between 
fluorophores: 409–485 nm for AMCA, 494–553 nm 
for GFP and 561-595 nm for Texas Red. For COX-2 
analysis, an in-house plugin was designed to calculate 
the co-localisation coefficients m1 (red) and m2 (green), 
before quantifying co-localisation between each pair of 
fluorescent markers, as previously described [54]. The 
plugin was designed to determine the percentage of co-
localisation between COX-2 staining (red) and each of the 
other cell markers (green), together with the percentage 
of area (within the image) of each marker that is above 
the user-defined threshold. All images were acquired at the 
same time and under the same conditions.
Nitrotyrosine (NT) was used as a marker of nitrated 
proteins and cell damage owing to the specific presence 
of nitric oxide (NO). At the same time, owing to its 
reported link with NO [21–23], levels of p53 expression 
were also quantified. To this end, 8 sections, spanning the 
region of metastasis, for each animal (n = 4 per group) 
were stained using an anti-NT antibody (1:300, Merck 
Millipore, Germany) and analysed in ImageScope using 
an algorithm that detects the number of brown pixels per 
section. NT area was normalised to tumour area for each 
brain metastasis assessed. A further 8 sections, adjacent to 
those used for NT analysis, were stained with an anti-p53 
damage induced nuclear protein (DINP) antibody (1:300, 
Santa Cruz biotech, H-110, USA) and the presence 
of p53 quantified as a percentage of tumour area using 
ImageScope. 
Immunohistochemical analysis of human tissue
Human brain metastasis resection samples, from 
breast carcinoma (n = 2) and lung adenocarcinoma 
(n = 3) patients, were obtained from the leading edge of 
brain metastases, as described previously [55]. All samples 
came from an approved Biobank (Walton Research Tissue 
Bank; National Research Ethics Service #11/WNo03/2). 
Sections from each primary tumour (4 μm formalin 
fixed paraffin-embedded) were dewaxed in xylene and 
rehydrated in decreasing concentrations of ethanol in 
water and then stained for LFA-1 and ICAM-1 as above, 
using anti-LFA-1 (1:300, Abcam, UK) and anti-ICAM-1 
(1:300, R&D systems, USA) antibodies.
Modulation of LFA-1 expression
Since LFA-1 is constitutively expressed in both 
tumour cell lines used above, we chose to assess the 
role of LFA-1 in the human cell line (MDA231Br-GFP) 
to increase the translational relevance of our findings 
downstream. To determine the role of this protein during 
tumour growth shRNA was used to knockdown LFA-1 
gene expression. Four different shRNA expression 
vectors were cloned in a pRFP-C-RS plasmid under the 
U6 promoter for mammalian cell expression specifically 
designed to bind ITGAL (CD11a) gene (Origene, USA). 
The shRNA plasmid was distinguished by puromycin 
resistance, and by red fluorophore (RFP) expression. Two 
different control plasmids were also produced; a purified 
and sequence-verified plasmid without shRNA cassette 
insert (shE) and a non-effective 29-mer scrambled shRNA 
cassette (shS). 
Cells were grown to 80–90% confluence in DMEM 
medium containing 10% fetal bovine serum and 1% 
L-glutamine at 37°C, with 5% CO2. At this point, cells 
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were digested with 0.25% trypsin solution containing 
0.01% EDTA, centrifuged at 1200 rpm for 5 min and 
plated onto a 6 well with 5 × 105 cells per well. The plates 
were incubated at 37°C with 5% CO2 overnight, and then 
the 6 groups of recombinant plasmid were transfected into 
the cells using Lipofectamine 2000 transfection reagent 
(Invitrogen, Carlsbad, CA) at a ratio of 1:1. After 6 h, 
RFP activity of the cells was detected by Leica fluorescent 
microscope (Olympus, Tokyo, Japan).
Following transfection of MDA231Br-GFP cells 
with shRNA against the LFA-1 gene, knockdown of 
protein expression was assessed by western blot. Total 
protein was extracted from five experimental cell lines; 
parental MDA231Br-GFP (MDA); shE; shS; and two 
clones with significant LFA-1 knockdown (KD#1 
and KD#2). Cells were lysed in buffer containing 
150 mM NaCl, 50 Mm Tris HCl pH 7.5, 5 mM EDTA 
pH 8.0, 1%Triton X-100, 0.1% SDS and protease 
inhibitors (cOmplete mini EDTA free, Roche). Protein 
concentrations for each sample were determined using 
the BCA protein assay kit (Fisher Scientific) according to 
the manufacturer’s instructions and equal amounts were 
loaded on 10–12% TGX pre-cast gels (Mini –PROTEAN, 
Bio-Rad Laboratories, UK). Proteins were separated by 
SDS PAGE under reducing conditions and transferred onto 
PVDF (Immobilon-P, Fisher Scientific) or nitrocellulose 
(Whatman Protan, GE Healthcare) membranes. 
Membranes were blocked in 5% non-fat milk in PBS 
and incubated overnight at 4°C with anti-CD11a (1:1000, 
Abcam) or anti-alpha tubulin (1:2000, DM1 eBioscience) 
antibodies. Proteins were detected using appropriate 
HRP conjugated secondary antibodies (Sigma, UK) and 
a chemiluminescent substrate system (Super Signal West 
Pico, Thermo Scientific). The mean intensity of each band 
was quantified with respect to the parental MDA231Br-
GFP cell line. Band densitometry was normalised to the 
intensity of tubulin bands and performed in triplicate.
To determine whether LFA-1 downregulation 
determined by Western blot reflected reduced expression of 
LFA-1 on the tumour cell surface, all experimental tumour 
cell lines were incubated with an anti-LFA-1 antibody 
(1:500, -MEM-83- Abcam, UK) for 30 minutes and then 
fixed and stained for LFA-1 detection (Supplementary 
Figure S7A–S7B). Further, stability of LFA-1 knockdown 
at later time points was assessed in MDA231Br-GFP cells 
after 7 passages (equivalent to day 20 after transfection) 
and retention of the plasmid (red fluorophore) was evident 
(Supplementary Figure S7C).  
MTT assay
To determine whether LFA-1 knock down in 
MDA231Br-GFP cells altered, the activity or proliferation 
of the different clones, we ran an MTT assay (Sigma-
Aldrich, Germany). Four different clones used in this work 
(MDA, shE, KD#1 and KD#2) were seeded in a 96 well 
plate at 5.000 cells per well. Every experimental group 
was measured in a spectrophotometer (absorbance λ570) 
at days 1, 2, 3, 4, 5 and 10 after seeding. At day 5 all 
clones were at ~100% confluency. Therefore, cells were 
plated again on a different 96 well plate and measured 
5 days later (day 10) to check that activity remained intact.
In vivo assessment of the effect of LFA-1 
knockdown on tumour growth
Five different sub-types of the MDA231Br-GFP 
cell line (MDA, shE, shS, KD#1 and KD#2) were injected 
intracerebrally in SCID mice, as described above. At 
day 14 and 21 after intracerebral tumour cell injection, 
animals were transcardially perfusion-fixed and the 
brains processed for histology as described above. To 
quantify tumour growth, 10 µm thick sections were cut 
across the entire striatum. Rostro-caudal growth of the 
tumours was determined from the distance between the 
most rostral and caudal sections containing tumour cells. 
All data were analysed blind to experimental conditions. 
To further assess tumour growth ImageScope software 
(Leica Microsystems, UK) was used to quantify tumour 
area for each animal (n = 6 per group) on at least 8 
sections evenly distributed through the striatum. Tumours 
were circumscribed and compared to the total brain area 
analysed. 
Effect of LFA-1 knockdown on downstream 
signalling pathways
To assess the effect of LFA-1 knockdown on the 
expression of genes downstream of LFA-1 signalling, 
mRNA levels of molecules involved in either LFA-1 or 
ICAM-1 (as the predominant ligand to LFA-1) activation 
pathways were quantified in brain tissue 14 days after 
tumour cell injection. Five groups of animals (n = 5 per 
group) were injected into the left striatum, as above, with 
MDA, shS, KD#1, KD#2, or PBS. Seven different genes 
were assessed: CXCL12, CXCR4, TGF-β, VEGF, COX-2, 
eNOS and iNOS. Five of the target genes were analysed 
for both human (h) and mouse (m) origin to determine 
whether changes observed reflected production by tumour 
cells (human mammary carcinoma) or host tissue (SCID 
mouse brain). Thus, 12 genes were assayed in total. 
Since no tumour growth changes were found between 
the two control shRNA groups (shE/shS), shS was used 
as the control group for all further experiments. Since no 
changes were found in any of the human genes studied, 
we further assessed the sensitivity of our technique by 
measuring the expression of a gene, vimentin, known to 
be highly expressed in the parental MDAMB231 cell line 
[56]. Human vimentin levels were quantified following the 
same protocol as above.
Quantitation of mRNA expression was performed with 
5 μl of cDNA, in a final volume of 20 μl containing 10 μl 
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SYBR Green master mixture from PrimerDesign Precision 
(UK) and 300 mM sense and antisense primers (See Table 2). 
RT-PCR was performed in a Stratagene RT-qPCR machine 
(Agilent, UK) with MxQPCR software (Agilent, UK), using 
the following amplification protocol: enzyme activation 10 
minutes at 95°C, denaturation 15s at 95°C and data collection 
1 min at 60°C. During the data collection phase, fluorogenic 
data was collected through the 6-carboxyfluorescein (FAM) 
channel, which detects Syber green.  A melt curve was 
also acquired at the end of the cycling. For mouse genes, 
qRT-PCR data were analysed in terms of fold expression 
in the four different MDA231Br cell lines used relative to 
averaged PBS injected control tissue. For the human genes, 
gene expression was compared with parental MDA groups. 
In both cases, the following equation was used:
Where GOI = gene of interest, HKG = housekeeping 
gene (CANX and GADPH for mouse and human tissue, 
respectively) and Ct = number of cycles required for 
the fluorescent signal to cross threshold (background 
fluorescent levels).
The relative levels of individual mRNA in each 
sample transcript compared to a control housekeeping 
gene were calculated using the 2-ΔΔCt method, where 
ΔΔCt = ΔCt sample – ΔCt reference. Here, ΔCt sample is the 
Ct value for any experimental sample normalised to the 
endogenous housekeeping gene and ΔCt reference is the Ct 
value for PBS samples also normalised to the endogenous 
housekeeping gene. Every experiment was run in duplicate 
and for the human genes, each gene was run twice on 
separate days.
In vitro investigation of the VEGF/NO/p53 axis
To further probe the potential link between VEGF 
production within the tumour environment, endothelial NO 
release and p53 production by tumour cells, MDA231Br-
GFP and KD#1 cells where co-cultured with either mouse 
(sEND1, kind gift from Dr. Robin Choudhury, UK) or human 
(hCMEC/D3; EMD Millipore SCC066) endothelial cells.
Endothelial cells were seeded at 1000 cells/well on 
a 24 transwell plate with 0,3 µm pores. 24 h later were 
incubated for 48 h with 20 ng/ml of recombinant VEGF 
or normal medium as control. After this time, a group of 
endothelial cells were assayed for NO production using 
a DAF-FM diacetate kit (ThermoFischer Scientific, 
US). Subsequently, the transwells with the cells were 
translocated onto a new 24 well plate in which either MDA 
or KD#1 tumour cells had been seeded at 5000 cell/well 
the day before. After 3 days of co-culture, tumour cells 
were harvested and p53 levels measured by western blot. 
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Table 2: Sequences of RT-PCR oligonucleotide primers




























































































Statistical analysis was performed using Prism 
(GraphPad Software Inc., USA). For the IHC quantitation, 
analysis of variance (ANOVA) was used to identify overall 
significant differences between the different time points or 
groups of animals, followed by Tukey post-hoc tests to 
identify specific differences between the groups.  All data 
are expressed as mean ± S.E.M.
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